clinical trial · NCT06039384
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
Advanced Solid TumorsINCB099280adagrasib
brief summary
The purpose of this study is to evaluate the safety and tolerability of INCB099280 in combination with adagrasib and to establish the MTD or identify RDE(s) for the combination of INCB099280 and adagrasib.
started
Dec 28, 2023
primary completion
Apr 11, 2025
completion
Jul 11, 2025
last updated
Sep 8, 2026
official title
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol